Abstract
The pharmacokinetics of antipyrine were studied in 12 healthy volunteers and 10 patients of Kenya African origin with Hodgkin's lymphoma. The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers. The antipyrine half-life in the patients with advanced Hodgkin's lymphoma was 17.1 +/- 2.7 h (mean +/- s.d.). The apparent volume of distribution was 0.72 +/- 0.14 l kg-1 (mean +/- s.d.) which was larger than in healthy volunteers (P less than 0.05). The total body clearance was 30.3 +/- 9.4 ml kg-1 h-1 (mean + s.d.) and this was reduced compared with that in healthy volunteers (P less than 0.02). After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BRODIE B. B., AXELROD J. The fate of antipyrine in man. J Pharmacol Exp Ther. 1950 Jan;98(1):97–104. [PubMed] [Google Scholar]
- Boobis A. R., Brodie M. J., Kahn G. C., Toverud E. L., Blair I. A., Murray S., Davies D. S. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol. 1981 Dec;12(6):771–777. doi: 10.1111/j.1365-2125.1981.tb01305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- D'Incalci M., Bolis G., Facchinetti T., Mangioni C., Morasca L., Morazzoni P., Salmona M. Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer. 1979 Jan;15(1):7–10. doi: 10.1016/0014-2964(79)90198-1. [DOI] [PubMed] [Google Scholar]
- Danhof M., Verbeek R. M., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol. 1982 Mar;13(3):379–386. doi: 10.1111/j.1365-2125.1982.tb01389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Faber O. K., Mouridsen H. T., Skovsted L. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol Toxicol (Copenh) 1974 Sep;35(3):195–200. doi: 10.1111/j.1600-0773.1974.tb00739.x. [DOI] [PubMed] [Google Scholar]
- Fraser H. S., Bulpitt C. J., Kahn C., Mould G., Mucklow J. C., Dollery C. T. Factors affecting antipyrine metabolism in West African villagers. Clin Pharmacol Ther. 1976 Sep;20(3):369–376. doi: 10.1002/cpt1976203369. [DOI] [PubMed] [Google Scholar]
- Prescott L. F., Adjepon-Yamoah K. K., Roberts E. Rapid gas-liquid chromatographic estimation of antipyrine in plasma. J Pharm Pharmacol. 1973 Mar;25(3):205–207. doi: 10.1111/j.2042-7158.1973.tb10625.x. [DOI] [PubMed] [Google Scholar]
- Yoshimura H., Shimeno H., Tsukamoto H. Metabolism of drugs. LXX. Further study on antipyrine metabolism. Chem Pharm Bull (Tokyo) 1971 Jan;19(1):41–45. doi: 10.1248/cpb.19.41. [DOI] [PubMed] [Google Scholar]